Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, will participate in the Virtual Investor Closing Bell Series on September 4, 2025 at 4:00 PM ET. During the event, CEO Abizer Gaslightwala will present a corporate overview focusing on the company's innovative payload platform for developing next-generation antibody drug conjugates (ADCs) in cancer treatment.
The event will feature a moderated discussion followed by a live Q&A session with investors. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days after the event.
Akari Therapeutics (Nasdaq: AKTX), una società biotecnologica operante in oncologia, parteciperà alla Virtual Investor Closing Bell Series il 4 settembre 2025 alle 16:00 ET. Durante l'evento il CEO Abizer Gaslightwala presenterà una panoramica aziendale concentrandosi sulla piattaforma di payload innovativa della società per lo sviluppo di anticorpi coniugati (ADC) di nuova generazione nel trattamento dei tumori.
L'incontro comprenderà una discussione moderata seguita da una sessione di domande e risposte in diretta con gli investitori. La presentazione sarà fruibile tramite webcast video live sul sito web della società e la registrazione sarà disponibile in replay per 90 giorni dopo l'evento.
Akari Therapeutics (Nasdaq: AKTX), una compañía biotecnológica en oncología, participará en la Virtual Investor Closing Bell Series el 4 de septiembre de 2025 a las 4:00 PM ET. Durante el evento, el CEO Abizer Gaslightwala ofrecerá una visión corporativa centrada en la innovadora plataforma de payload de la empresa para desarrollar conjugados anticuerpo-fármaco (ADC) de nueva generación en el tratamiento del cáncer.
El evento incluirá una charla moderada seguida de una sesión de preguntas y respuestas en vivo con inversores. La presentación será accesible mediante una transmisión de video en vivo en la página web de la compañía y la repetición estará disponible durante 90 días después del evento.
Akari Therapeutics (Nasdaq: AKTX)는 종양학 분야의 바이오테크 기업으로, 2025년 9월 4일 오후 4시(동부시간)에 열리는 Virtual Investor Closing Bell Series에 참여합니다. 행사에서 CEO Abizer Gaslightwala는 차세대 항체-약물 접합체(ADC) 개발을 위한 회사의 혁신적 페이로드 플랫폼을 중심으로 기업 개요를 발표할 예정입니다.
행사는 진행자가 이끄는 토론과 투자자 대상 라이브 Q&A 세션으로 구성됩니다. 발표는 회사 웹사이트를 통한 라이브 비디오 웹캐스트로 시청할 수 있으며, 행사 후 90일 동안 재방송으로 제공됩니다.
Akari Therapeutics (Nasdaq: AKTX), une société biotechnologique en oncologie, participera à la Virtual Investor Closing Bell Series le 4 septembre 2025 à 16h00 ET. Lors de l'événement, le PDG Abizer Gaslightwala présentera une vue d'ensemble de l'entreprise en mettant l'accent sur la plateforme de payload innovante de la société pour développer des conjugués anticorps-médicament (ADC) de nouvelle génération dans le traitement du cancer.
L'événement comprendra une discussion animée suivie d'une session de questions-réponses en direct avec les investisseurs. La présentation sera accessible via une diffusion vidéo en direct sur le site web de la société, et un replay sera disponible pendant 90 jours après l'événement.
Akari Therapeutics (Nasdaq: AKTX), ein Biotechnologieunternehmen im Bereich Onkologie, wird an der Virtual Investor Closing Bell Series am 4. September 2025 um 16:00 Uhr ET teilnehmen. Während der Veranstaltung wird CEO Abizer Gaslightwala einen Unternehmensüberblick geben, mit Schwerpunkt auf der innovativen Payload-Plattform des Unternehmens zur Entwicklung von Antikörper-Wirkstoff-Konjugaten (ADCs) der nächsten Generation zur Krebsbehandlung.
Die Veranstaltung umfasst eine moderierte Diskussion, gefolgt von einer Live-Fragerunde mit Investoren. Die Präsentation ist über einen Live-Video-Webcast auf der Unternehmenswebsite zugänglich; ein Replay steht für 90 Tage nach der Veranstaltung zur Verfügung.
- None.
- None.
Live moderated webcast on Thursday, September 4th at 4:00 PM ET
Access the event here
BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that it will participate in the Virtual Investor Closing Bell Series on Thursday, September 4, 2025 at 4:00 PM ET.
As part of the event, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will provide a corporate overview and discuss its innovative payload platform fueling a pipeline of next-generation ADCs designed with novel immuno-oncology payloads to address a wide range of cancer tumor targets. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
The live video webcast will be available in the Investors section of the Company’s website (akaritx.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome modulator designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing modulator has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
When is Akari Therapeutics (AKTX) presenting at the Virtual Investor Closing Bell Series?
Who will be presenting at the AKTX Virtual Investor event?
Where can I watch the Akari Therapeutics (AKTX) Virtual Investor presentation?
What topics will be covered in the AKTX Virtual Investor presentation?
